Results 21 to 30 of about 710,958 (307)

Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments [PDF]

open access: yes, 2021
Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed.

core   +2 more sources

Non‐small cell lung cancer in China

open access: yesCancer Communications, 2022
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer
Peixin Chen   +3 more
doaj   +1 more source

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]

open access: yes, 2006
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael   +8 more
core   +1 more source

Non-small-cell lung cancer: how to manage BRAF-mutated disease

open access: yesDrugs in Context, 2023
BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes
Giorgia Guaitoli   +5 more
doaj   +1 more source

MYC is a metastasis gene for non-small-cell lung cancer. [PDF]

open access: yes, 2009
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn   +26 more
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A.   +15 more
core   +1 more source

Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]

open access: yes, 2013
Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Hennen, Elisabeth   +19 more
core   +1 more source

Prognostic significance of folate metabolism polymorphisms for lung cancer. [PDF]

open access: yes, 2007
Functional nonsynonymous single-nucleotide polymorphisms (nsSNPs) of folate metabolism genes can influence the methylation of tumour suppressor genes, thereby potentially impacting on tumour behaviour.
El Galta, R   +13 more
core   +1 more source

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

open access: yes, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G.   +25 more
core   +1 more source

Staging non-small cell lung cancer [PDF]

open access: yesCancer Imaging, 2007
Patients with newly diagnosed non-small cell lung cancer (NSCLC) need accurate tumor staging in order to direct appropriate therapy and establish prognosis; the tumor is usually staged using the TNM system. The major imaging modalities currently used for staging this disease are thoracic computed tomography (CT) (including the adrenal glands) and whole
openaire   +2 more sources

Home - About - Disclaimer - Privacy